GSK, Germany push coronavirus-focused mRNA player CureVac's latest round to $640M
After courting some high-profile investors, CureVac has closed a whopping $640 million (€560 million) in its latest round.
The biotech announced the financing in a brief press release, noting that previously disclosed investments from the German federal government and GlaxoSmithKline accounted for $514 million of the total. Qatar Investment Authority and other existing as well as new investors contributed the rest.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 118,000+ biopharma pros reading Endpoints daily — and it's free.